Pro-urokinase clot-dissolving drug for stroke in the back of the brain, treated later
Tests pro-urokinase in adults with a stroke in the brain's back circulation.
Plain-language title generated from the registry record
Registry title: Pro-urokinase for Extended-Window Posterior Circulation Stroke
Key facts
- Where
- Zhengzhou, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked blood vessel at the back of the brain. Treatment starts 4.5 to 9 hours after symptoms began, and thrombectomy is not planned.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Acute ischemic stroke; symptoms began 4.5-9 hours before enrollment (wake-up and unwitnessed strokes included); MRI shows a limited infarct core (DWI-FLAIR mismatch); NIHSS score 4-25
- Earlier treatment
- No planned endovascular treatment; no heparin within 24 hours; no oral anticoagulation therapy; no other interventional trial in the previous 3 months
Main reasons for not taking part
- Planned endovascular treatment (thrombectomy)
- Bleeding in the brain, history of brain bleeding, or active internal bleeding
- Stroke or serious head injury within 3 months
- Systolic blood pressure 185 mmHg or higher, or diastolic 110 mmHg or higher
- Pregnancy
Read by machine on 9 November 2026.
Where in China
- Department of Neurology, the First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Zhengzhou University
- Trial code
- NCT07617870
- Record updated
- 1 June 2026
- Original description
This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.Read full original descriptionShow less
Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study
This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.
Inclusion: Age ≥ 18 years; AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed); Imaging criteria:; DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR; DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory; NIHSS score 4-25; First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1); Signed informed consent from the patient or legally authorized representative.
Exclusion: Intracranial or spinal cord surgery within 3 months; Heparin therapy within 24 hours; Oral anticoagulation therapy; Major surgery within 1 month; Gastrointestinal or urinary tract hemorrhage within the previous 30 days; Participation in other interventional clinical trials within the previous 3 months; Subarachnoid or intracranial hemorrhage; History of intracranial hemorrhage; Active internal hemorrhage; Neurological deficit after epileptic seizures; Myocardial infarction within 3 months; Allergy to study drugs; Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; platelet count of <100000/mm3; Oral warfarin is being taken and INR>1.6 or APTT abnormal; Blood glucose < 50 mg/dl (2.7mmol/L); Planned endovascular treatment; Contradictory to MRI examination; MRI image not qualified for evaluation; Serious neurological deficits before onset (mRS≥2); Obvious head injuries or strokes within 3 months; Intracranial tumor, arteriovenous malformation or aneurysm; Aortic arch dissection; Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg; Pregnancy; Unlikely to adhere to the trial protocol or follow-up.